Cargando…

Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response

In a recent phase I clinical trial, a vaccine consisting of glypican-3 (GPC3)-derived CTL epitopes was found to be safe and induced measurable immune and clinical responses in patients with hepatocellular carcinoma (HCC). The aim of this study was to identify GPC3-derived long peptides (GPC3-LPs) ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sayem, Mohammad A., Tomita, Yusuke, Yuno, Akira, Hirayama, Masatoshi, Irie, Atsushi, Tsukamoto, Hirotake, Senju, Satoru, Yuba, Eiji, Yoshikawa, Toshiaki, Kono, Kenji, Nakatsura, Tetsuya, Nishimura, Yasuharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760284/ https://www.ncbi.nlm.nih.gov/pubmed/26942076 http://dx.doi.org/10.1080/2162402X.2015.1062209

Ejemplares similares

Establishment of HLA-DR4 Transgenic Mice for the Identification of CD4(+) T Cell Epitopes of Tumor-Associated Antigens
por: Yatsuda, Junji, et al.
Publicado: (2013)

Identification of immunogenic LY6K long peptide encompassing both CD4(+) and CD8(+) T-cell epitopes and eliciting CD4(+) T-cell immunity in patients with malignant disease
por: Tomita, Yusuke, et al.
Publicado: (2014)

An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs
por: Hirayama, Masatoshi, et al.
Publicado: (2016)

Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology
por: Imamura, Yuya, et al.
Publicado: (2016)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age
por: Tsukamoto, Hirotake, et al.
Publicado: (2015)

Immune‐suppressive effects of interleukin‐6 on T‐cell‐mediated anti‐tumor immunity
por: Tsukamoto, Hirotake, et al.
Publicado: (2017)

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

Identification of an H2-K(b) or H2-D(b) restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
por: IWAMA, TATSUAKI, et al.
Publicado: (2013)

Cancer therapy with major histocompatibility complex‐deficient and interferon β‐producing myeloid cells derived from allogeneic embryonic stem cells
por: Umemoto, Satoshi, et al.
Publicado: (2019)

Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3
por: Kawashima, Issei, et al.
Publicado: (2015)

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
por: TADA, YOSHITAKA, et al.
Publicado: ( 201)

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case
por: Sawada, Yu, et al.
Publicado: (2013)

Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis
por: Taniguchi, Masatake, et al.
Publicado: (2020)

Suppression of Th1-Mediated Autoimmunity by Embryonic Stem Cell-Derived Dendritic Cells
por: Ikeda, Tokunori, et al.
Publicado: (2014)

Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses
por: Nishimura, Yasuharu, et al.
Publicado: (2015)

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008)

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
por: Suzuki, Shiro, et al.
Publicado: (2014)

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2016)

Generation of functional CD8+ T Cells by human dendritic cells expressing glypican-3 epitopes
por: O'Beirne, James, et al.
Publicado: (2010)

Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model
por: Fujinami, Norihiro, et al.
Publicado: (2016)

Drosophila glypicans regulate the germline stem cell niche
por: Hayashi, Yoshiki, et al.
Publicado: (2009)

Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma
por: Suzuki, Shiro, et al.
Publicado: (2016)

Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma
por: Ukai, Mayu, et al.
Publicado: (2021)

Immunotherapy with 4-1BBL-Expressing iPS Cell‐Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma
por: Kuriyama, Haruka, et al.
Publicado: (2021)

Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia
por: Raeisi, Mortaza, et al.
Publicado: (2019)

Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery
por: Miura, Masahiro, et al.
Publicado: (2020)

Plasma and tumoral glypican‐3 levels are correlated in patients with hepatitis C virus‐related hepatocellular carcinoma
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response
por: Mashima, Hiroaki, et al.
Publicado: (2020)

Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events
por: Tsukamoto, Hirotake, et al.
Publicado: (2022)

The overexpression of glypican-5 promotes cancer cell migration and is associated with shorter overall survival in non-small cell lung cancer
por: LI, YAN, et al.
Publicado: (2013)

Low Expression of CD5 and CD6 Is Associated with Poor Overall Survival for Patients with T-Cell Malignancies
por: Sui, Songnan, et al.
Publicado: (2022)

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
por: Waaijer, Stijn JH, et al.
Publicado: (2020)

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
por: Shitara, Kohei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_li95dncn2oe0ufeqltve0k3hpf